KARL STORZ SE & Co. KG

Company Snapshot

Founded: 1945
Entity Type: Public
Employees: 9400
Region: Germany
Revenue: $2347.0 Millions
Revenue Year: 2023
Segment: Human and Veterinary Medicine
Headquarter: Tuttlingen, Germany
Key Geographics: Germany, U.S., Switzerland, Estonia
Corporate Address: Dr.-Karl-Storz-Straße 34, 78532 Tuttlingen Germany Tel. +49-7461-708-0 www.karlstorz.com/de/de/index.htm

Company Overview

Karl Storz was founded in 1945 and is a family-owned global medical technology company. The company operates in two business areas- Human & Veterinary Medicine. The company offers more than 15,000 products for human and veterinary medicine products. In the human business area, the company provides neurosurgery, oral and maxillofacial surgery, otorhinolaryngology, plastic surgery, anesthesiology and emergency medicine, thorax, gastroenterology, laparoscopy in surgery, gynecology, urology, gynecology, proctology, arthroscopy and sports medicine, spine surgery, microscopy, pediatrics, and cross-disciplinary items. Karl Storz offers bronchoscopes are offered under the human business area.

The company has a strong market presence with 70 subsidiaries in more than 40 countries. It has over 100 training centers and production sites in Germany, U.S., Switzerland, and Estonia. The company employs 8,300 people globally – with 3,000 employees in the Tuttlingen region alone.

KARL STORZ SE & Co. KG In Reports

Colonoscopes: Global Markets

According to our Research Report the colonoscopes market report includes global revenue ($ Million) for base year data for 2023 and estimated data for the forecast period 2024 through 2029.

Global Bronchoscopy Market

BCC Research Market Report says global bronchoscopy market should reach $3.9 billion by 2028 from $2.7 billion in 2023 at a compound annual growth rate of 7.4%.

Operating Room Equipment and Software: Global Markets

BCC Research Market Report says global market for operating room equipment and software reached $26.1 billion in 2022 and estimated to increase from $27.8 billion in 2023 to reach $38.9 billion by 2028.

Company's Business Segments

  • Human Medicine : This segment serves Airway Management, Arthroscopy, Sports Medicine, Bronchoscopy, Otorhinolaryngology, Gastroenterology, Visceral Surgery, Gynecology, Neurosurgery, Pediatric Surgery, Spine Surgery, Thoracic Surgery, Urology.
  • Veterinary Medicine : This segment includes medicines for Avian and Exotic Animals, Large Animals, Small Animals.

Applications/End User Industries

  • Sports Medicine
  • Gastroenterology
  • Gynecology
  • Neurosurgery
  • Pediatrics
  • Otorhinolaryngology
  • Veterinary
  • Visceral Surgery
  • Bronchoscopy